Abstract: Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects.

Abstract: Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects.

Abstract: The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.

Abstract: The conversion of nootkatol to nootkatene in a terpene blend is intentionally caused by adding a catalytically effective amount of at least one compound that catalyzes the reaction of nootkatol to nootkatene to the terpene blend containing nootkatol. Methods of preparing terpene blends, terpene blends, flavour compositions containing the terpene blends, beverages and foodstuffs containing the flavour compositions, fragrance compositions containing the terpene blends, and fragranced products containing the fragrance composition are also disclosed.

Abstract: The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadliesive polymeric diffusion environment and a barrier environment.

Abstract: The conversion of nootkatol to nootkatene in a terpene blend is mitigated or prevented by substantially or completely separating the nootkatols such as a-nootkatol from compounds present in the terpene blend that catalyze the chemical reaction of nootkatol to nootkatene, and/or by at least partially neutralizing the compounds present in the terpene blend that catalyze the chemical reaction of nootkatol to nootkatene. Methods of preparing terpene blends, terpene blends, flavour compositions containing the terpene blends, beverages and foodstuffs containing the flavour compositions, fragrance compositions containing the terpene blends, and fragranced products containing the fragrance composition are also disclosed.

Abstract: An assembly for an electric vehicle charger. The assembly comprising an electric vehicle charger housing having a first side wall, a second side wall and a porous membrane providing gas communication between an interior and exterior of the housing. Arranged within the housing are one or more electronics modules, an output circuit, and a heat exchanger. The assembly also includes a first air channel located between the one or more electronics modules and the first side wall of the housing, the first air channel being in fluid communication with the output circuit and the heat exchanger, and a second air channel located between the one or more electronics modules and the second side wall of the housing, the second air channel being in fluid communication with the output circuit and the heat exchanger.

Abstract: A modular electronics assembly comprising: removable electronic modules comprising a module housing containing electronic circuitry and bearing a module electrical connector coupled to the electronic circuitry each removable electronic module having a first alignment formation; an enclosure having an interior dimensioned to contain the removable electronic modules therein, the enclosure including, one or more enclosure electrical connectors corresponding to one or more of the module electrical connectors for establishing a connection, guide members extending into the interior of the enclosure for guiding respective ones of the module housings toward the enclosure electrical connectors; second alignment formations each arranged to cooperate with a respective first alignment formation of the removable electronic modules for aligning module electrical connectors with enclosure electrical connectors to thereby establish connection; wherein the first alignment formations are positioned on the module housings to re

Abstract: An electric vehicle charging system comprising a Direct Current (DC) distributor, a site controller, one or more alternating current (AC)/DC rectifiers connected to the DC distributor and the site controller, and an electric vehicle charger having one or more DC/DC converters connected to the DC distributor and a charge controller in communication with the site controller and each of the one or more DC/DC converters. The one or more AC/DC rectifiers are decoupled from the one or more DC/DC converters.

Abstract: The conversion of nootkatol to nootkatene in a terpene blend is intentionally caused by adding a catalytically effective amount of at least one compound that catalyzes the reaction of nootkatol to nootkatene to the terpene blend containing nootkatol. Methods of preparing terpene blends, terpene blends, flavour compositions containing the terpene blends, beverages and foodstuffs containing the flavour compositions, fragrance compositions containing the terpene blends, and fragranced products containing the fragrance composition are also disclosed.

Abstract: The present invention relates to a pharmaceutical dosage form for transmucosal delivery of an active agent to two or more mucosal surfaces. The dosage form is presented as a transmucosal delivery device. The devices of the invention may include at least two mucoadhesive surfaces. The devices may further include an intermediate layer disposed between the mucoadhesive layers. The pharmaceutical can be incorporated in any one or all of the mucoadhesive layers or the intermediate layer. Upon application, the device adheres to at least two surfaces, providing transmucosal delivery of the drug to at least two surfaces.

Abstract: Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects.

Abstract: The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.

Abstract: The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.

Abstract: The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.

Abstract: The present invention relates to methods and compositions for treating pain in a subject and safely transitioning a subject from a full ?-opioid receptor agonist to a partial ?-opioid receptor agonist.

Abstract: A unitary fastener and cable guidance device is operable with a pulley block assembly for stringing cable across towers. The device guides a cable onto a sheave wheel of the assembly, while fastening directly to the assembly through a unitary cantilevered axle. The one-piece design comprises a pair of discs forming an annular depression there between, and a cantilevered axle extending from the outer side of one disc. This unitary configuration reduces the number of fasteners and other components. Since the cantilevered axle is the fastening mechanism, rather than a separate fastener passing through a hole through the center of the device, the minimum outer diameter of the annular depression can be smaller than the outer diameter of the cantilevered axle, allowing the central portion of the device to be smaller and thus its sides to be higher, which helps hold the cable more robustly within the device.

Abstract: The present invention relates to a solid pharmaceutical dosage form for abusable drug delivery with reduced illicit abuse potential. The dosage form is presented as a bioerodable transmucosal delivery device that includes an abusable drug and an antagonist to the abusable drug associated with an abuse-resistant matrix. The devices of the invention may be in the form of a layered film or a tablet. Upon application in a non-abusive manner, the device adheres to the mucosal surface, providing transmucosal drug delivery of the drug with minimal absorption of the antagonist into systemic circulation.

Abstract: The present invention relates to a pharmaceutical dosage form for transmucosal delivery of an active agent to two or more mucosal surfaces. The dosage form is presented as a transmucosal delivery device. The devices of the invention may include at least two mucoadhesive surfaces. The devices may further include an intermediate layer disposed between the mucoadhesive layers. The pharmaceutical can be incorporated in any one or all of the mucoadhesive layers or the intermediate layer. Upon application, the device adheres to at least two surfaces, providing transmucosal delivery of the drug to at least two surfaces.

Abstract: The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.